Viatris (VTRS)

Viatris (VTRS-Q) is a company that currently finds itself in a challenging position, as indicated by the mixed reviews from experts. The first review suggests that while the stock trades at a low price-to-earnings ratio of 7-8x, there is concern about its growth potential and the need for a stronger focus on creating shareholder value. This indicates potential opportunities for improvement if managed correctly. The second expert highlights that Viatris, which was spun out of Pfizer, has a limited market presence and is viewed as a small-cap stock. The general sentiment is cautious, with an emphasis on finding companies in the health care sector that are undervalued. Overall, while there might be upside in the stock's performance, its current attributes raise questions among analysts regarding its long-term growth trajectory.